GLA and Fabry disease: To assess the end-organ damage and impact of ERT (including treatment with agalsidase-alfa [0.2 mg/ kg i.v. body weight every other week], agalsidase-beta [1.0 mg/ kg i.v. body weight every other week]) or chaperone therapy (migalastat, 123 mg orally every other day), 102 female patients with genetically confirmed FD were recruited at 6 FD centers (Fig. 1).